Proactive Investors - Finance
15 Nov 2025, 09:28 UTC · 44w ago
Verdict
Headline takes no side. We score IMUX +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Immunic's CALLIPER study demonstrated a statistically significant effect on confirmed disability improvement for its oral MS treatment, vidofludimus calcium.
So whatStatistically significant efficacy data in clinical trials is the primary driver of valuation for biotech firms.
More positive than 99% of claims this week
Data from the EMPhASIS phase 2 open-label extension showed 92.3% of patients remained free of 12-week confirmed disability worsening after 144 weeks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
Topline data from the ENSURE phase 3 trials in relapsing MS are expected in 2026.
More positive than 78% of claims this week
Recently granted US patents for vidofludimus calcium may extend commercial exclusivity beyond 2041.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported statistically significant clinical trial results, positive drug durability data, and newly granted US patents.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+20.0%
Price agrees with the score
$9.35 vs $7.79 close before publication (Nov 14) · not market-adjusted
IMUX chart →
